期刊
ONCOLOGIST
卷 26, 期 11, 页码 E2082-E2085出版社
WILEY
DOI: 10.1002/onco.13903
关键词
Ruxolitinib; Discontinuation; Hypoxemic respiratory failure; Allogeneic hematopoietic cell transplantation
类别
Ruxolitinib, a selective inhibitor of Janus kinases 1 and 2, is increasingly used in allogeneic hematopoietic cell transplantation (HCT) recipients, with potential complications including acute hypoxemic respiratory failure upon discontinuation. However, systemic corticosteroids and reinitiation of ruxolitinib have shown to result in rapid clinical improvement in affected patients. Further research is necessary to characterize the biological and clinical effects of ruxolitinib discontinuation in this patient population.
Ruxolitinib, a selective inhibitor of Janus kinases 1 and 2, is increasingly being used in allogeneic hematopoietic cell transplantation (HCT) recipients following its approval by the U.S. Food and Drug Administration for the treatment of steroid-refractory acute graft-versus-host disease. Although there is extensive experience using ruxolitinib for patients with myeloproliferative neoplasms, the biologic effects and clinical implications of its dosing, tapering, and discontinuation for allogeneic HCT recipients are incompletely characterized. We describe three allogeneic HCT recipients who developed acute hypoxemic respiratory failure within 3 months of ruxolitinib discontinuation. Radiographic findings included marked bilateral ground-glass opacities. Systemic corticosteroids and reinitiation of ruxolitinib resulted in rapid clinical improvement in all three patients. All three patients achieved a significant clinical response, with decrease in oxygen requirement and improvement in radiographic changes. Given the increasing use of ruxolitinib in allogeneic HCT recipients, there is significant impetus to characterize the biologic and clinical effects resulting from discontinuation of ruxolitinib, to better tailor treatment plans and prevent potential adverse effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据